PMID: 6991407Mar 1, 1980Paper

Hypotensive action of captopril and saralasin in intact and anephric spontaneously hypertensive rats

Hypertension
J S HutchinsonA E Doyle

Abstract

Intravenous injection of the converting enzyme inhibitor SQ14,225 (captopril, 2 mg/kg) reduced the blood pressure of anesthetized, spontaneously hypertensive rats (SHR) progressively over a 3-hour period. An indistinguishable fall in blood pressure occurred in SHR that were bilaterally nephrectomized 1 hour prior to injection of the converting enzyme inhibitor. In the nephrectomized animals, plasma renin activity (PRA) had fallen to less than 30% of its initial values at the time of injection. Injection of the vehicle alone had no effect on blood pressure in either anephric or intact SHR. The converting enzyme inhibitor produced no significant change in the blood pressure of either intact or anephric normotensive Wistar-Kyoto (NT-WK) rats. Infusions of Sar1-Ala8-angiotensin II (saralasin, 10 micrograms/kg-1/min-1) similarly reduced blood pressure of both intact and anephric SHR. These results indicate that captopril and saralasin lower blood pressure in the SHR by some mechanism(s) independent of the kidneys, circulating renin, or bradykinin potentiation. It is suggested that angiotensin II, locally produced at some critical tissue site(s), is involved in the maintenance of raised blood pressure in SHR.

References

Jan 1, 1978·Neuroendocrinology·M I Phillips
Mar 15, 1976·The Biochemical Journal·B J Morris, C I Johnston
May 4, 1978·The New England Journal of Medicine·H GavrasD N McKinstry
Mar 1, 1976·Clinical and Experimental Pharmacology & Physiology·D GantenH Fischer
Feb 1, 1976·The American Journal of Physiology·T E Lohmeier, J O Davis
Nov 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·S FinkielmanV E Nahmod
Nov 1, 1974·Clinical and Experimental Pharmacology & Physiology·H F OatesG S Stokes
Apr 1, 1972·Proceedings of the Society for Experimental Biology and Medicine·W De JongA Sjoerdsma
Mar 1, 1964·The Journal of Experimental Medicine·A B GOULDJ R KAHN

❮ Previous
Next ❯

Citations

Sep 6, 2000·Clinical and Experimental Pharmacology & Physiology·J M BonnetJ Sassard
Jun 1, 1992·Journal of the American College of Nutrition·D E Grobbee
Jul 1, 1981·Clinical and Experimental Pharmacology & Physiology·R DiNicolantonioF A Mendelsohn
Mar 1, 1983·Clinical and Experimental Pharmacology & Physiology·Y TakataA E Doyle
May 1, 1984·Clinical and Experimental Pharmacology & Physiology·R Di NicolantonioA E Doyle
Aug 13, 2013·Expert Opinion on Investigational Drugs·Shigehiko MizutaniHiroshi Kobayashi
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice·J M MeyerJ A Weyhenmeyer
Jan 1, 1986·Clinical and Experimental Hypertension. Part A, Theory and Practice·H SuzukiK Kondo
Dec 21, 2004·Vascular Pharmacology·Jesus R Castillo-HernandezRafael Rubio
Apr 21, 1982·The American Journal of Cardiology·R DiNicolantonioA E Doyle
Mar 1, 1981·Circulation Research·N C Trippodo, E D Frohlich
May 12, 2019·The Journal of Physiology·J Shane HooperThomas E Taylor-Clark
Aug 26, 2006·Biotechnology and Bioengineering·B H Junker, H Y Wang
Sep 1, 1983·Basic Research in Cardiology·G ErtlR A Kloner
Jul 1, 1982·The American Journal of Physiology·H SuzukiT Saruta

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.